Rheumatology — Medicare Part B billing by state
202 physician groups whose primary specialty is Rheumatology billed $0.70B to Medicare fee-for-service in 2024.
Calendar year 2024 · Medicare fee-for-service Part B
| State | Groups | Services | Beneficiary-episodes | Medicare payments | Standardized payments ↓ | Payments / group | Services / group |
|---|---|---|---|---|---|---|---|
| Florida | 22 | 9,907,341 | 197,180 | $99,784,979 | $98,417,169 | $4,535,681 | 450,334 |
| California | 27 | 5,753,785 | 188,101 | $65,124,161 | $62,881,320 | $2,412,006 | 213,103 |
| Arizona | 5 | 4,433,100 | 111,056 | $49,646,726 | $49,466,235 | $9,929,345 | 886,620 |
| South Carolina | 9 | 3,723,540 | 77,471 | $40,356,397 | $40,958,219 | $4,484,044 | 413,727 |
| North Carolina | 11 | 2,857,666 | 69,586 | $32,042,006 | $32,180,992 | $2,912,910 | 259,788 |
| New York | 10 | 2,461,082 | 119,699 | $32,268,086 | $31,379,964 | $3,226,809 | 246,108 |
| Texas | 23 | 3,069,903 | 109,941 | $31,177,346 | $31,354,146 | $1,355,537 | 133,474 |
| Maryland | 9 | 2,626,004 | 84,916 | $30,588,733 | $29,896,537 | $3,398,748 | 291,778 |
| Pennsylvania | 11 | 2,299,881 | 46,732 | $28,005,509 | $27,531,346 | $2,545,955 | 209,080 |
| New Jersey | 6 | 2,459,159 | 53,151 | $26,976,056 | $26,429,656 | $4,496,009 | 409,860 |
| Virginia | 11 | 2,473,267 | 44,858 | $23,788,521 | $23,552,397 | $2,162,593 | 224,842 |
| Georgia | 10 | 1,961,603 | 56,374 | $21,215,214 | $21,262,376 | $2,121,521 | 196,160 |
| Alabama | 5 | 1,531,562 | 59,830 | $20,698,171 | $20,970,119 | $4,139,634 | 306,312 |
| Kentucky | 6 | 1,944,870 | 24,459 | $16,779,011 | $17,161,986 | $2,796,502 | 324,145 |
| Kansas | 3 | 1,431,110 | 36,146 | $14,922,366 | $14,996,464 | $4,974,122 | 477,037 |
| Tennessee | 6 | 1,375,028 | 36,809 | $14,669,617 | $14,973,328 | $2,444,936 | 229,171 |
| Louisiana | 4 | 1,057,996 | 23,587 | $12,864,986 | $13,030,891 | $3,216,247 | 264,499 |
| Indiana | 8 | 1,217,982 | 27,160 | $12,259,559 | $12,357,581 | $1,532,445 | 152,248 |
| Missouri | 1 | 1,097,395 | 28,944 | $12,021,814 | $12,142,068 | $12,021,814 | 1,097,395 |
| Ohio | 5 | 1,023,283 | 29,875 | $11,071,609 | $11,171,962 | $2,214,322 | 204,657 |
| Colorado | 3 | 905,456 | 15,070 | $10,406,979 | $10,360,228 | $3,468,993 | 301,819 |
| Illinois | 5 | 1,083,409 | 30,599 | $10,107,848 | $10,087,943 | $2,021,570 | 216,682 |
| Iowa | 2 | 785,750 | 43,166 | $9,536,720 | $9,576,178 | $4,768,360 | 392,875 |
| Minnesota | 3 | 700,236 | 26,498 | $9,408,733 | $9,442,349 | $3,136,244 | 233,412 |
| Oregon | 3 | 688,249 | 16,372 | $9,305,387 | $9,352,242 | $3,101,796 | 229,416 |
| Oklahoma | 1 | 815,408 | 13,993 | $8,494,198 | $8,602,517 | $8,494,198 | 815,408 |
| Arkansas | 3 | 764,992 | 8,672 | $8,348,799 | $8,453,355 | $2,782,933 | 254,997 |
| Michigan | 7 | 629,265 | 15,763 | $7,806,567 | $7,944,358 | $1,115,224 | 89,895 |
| Wisconsin | 3 | 530,018 | 30,996 | $7,619,719 | $7,675,827 | $2,539,906 | 176,673 |
| Idaho | 2 | 363,254 | 10,049 | $4,694,925 | $4,797,152 | $2,347,462 | 181,627 |
| Massachusetts | 3 | 280,620 | 22,890 | $3,605,994 | $3,530,443 | $1,201,998 | 93,540 |
| Washington | 2 | 300,814 | 4,150 | $3,009,368 | $2,961,746 | $1,504,684 | 150,407 |
| New Mexico | 1 | 240,304 | 2,121 | $2,687,512 | $2,724,620 | $2,687,512 | 240,304 |
| Rhode Island | 2 | 300,721 | 3,375 | $2,413,810 | $2,381,944 | $1,206,905 | 150,360 |
| District of Columbia | 3 | 193,725 | 8,560 | $2,083,583 | $2,001,391 | $694,528 | 64,575 |
| Utah | 2 | 376,705 | 2,118 | $1,727,566 | $1,728,480 | $863,783 | 188,352 |
| Nevada | 1 | 133,731 | 2,484 | $1,440,278 | $1,457,897 | $1,440,278 | 133,731 |
| Connecticut | 5 | 72,309 | 6,198 | $1,351,735 | $1,284,063 | $270,347 | 14,462 |
| Maine | 1 | 76,716 | 3,374 | $522,959 | $519,620 | $522,959 | 76,716 |
| New Hampshire | 1 | 677 | 497 | $35,979 | $38,808 | $35,979 | 677 |
| Alaska | 1 | 172 | 127 | $24,883 | $26,479 | $24,883 | 172 |
| PR | 1 | 316 | 183 | $22,813 | $24,026 | $22,813 | 316 |
Need this specialty's market in one document?
Notify me at launchEach group carries one specialty label — the specialty most common among its clinicians in CMS's Doctors and Clinicians register — so every figure on this page counts groups, not individual clinicians. An organization's entire Medicare billing is credited to that one label, so a specialty's totals reflect how organizations are labeled, not the specialty of each service; large multi-specialty organizations — where no single specialty is a majority of the clinicians — account for much of the volume shown under many specialties. Totals include only volume that can be credited to a single group; clinicians registered with more than one group are left out of group totals and shown as “—” elsewhere on Nevvi. Clinicians not registered with any group, and groups without a specialty label, are also not included. A group is counted in every state its clinicians bill Medicare from, so state figures overlap and never sum to the national figure.
All figures are Medicare fee-for-service Part B only; Medicare Advantage claims are not included. Cross-state comparisons use standardized payments, which remove regional differences in what Medicare pays; services without a standardized amount — mainly Part B drugs — are not in that column, and the Medicare payments column shows what Medicare actually paid. Beneficiary counts are beneficiary-episodes: one person treated in more than one setting or state is counted in each.
Top codes by Medicare payments CY2024
| Code | Services | Medicare payments ↓ | Largest state markets |
|---|---|---|---|
| J0129 · Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 4,582,912 | $154,007,112 | FLCAAZSCNC |
| J0897 · Injection, denosumab, 1 mg | 4,417,594 | $90,209,790 | FLCAAZSCNC |
| J0717 · Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 21,408,241 | $76,898,999 | FLCAAZSCNC |
| J1602 · Injection, golimumab, 1 mg, for intravenous use | 7,117,657 | $63,999,508 | FLCAAZSCNC |
| J3262 · Injection, tocilizumab, 1 mg | 12,889,713 | $60,184,810 | FLCAAZSCNC |
| 99214 · Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 480,779 | $44,187,473 | FLCAAZSCNC |
| J3111 · Injection, romosozumab-aqqg, 1 mg | 4,826,010 | $40,685,977 | FLCAAZSCNC |
| J1745 · Injection, infliximab, excludes biosimilar, 10 mg | 1,453,154 | $35,700,623 | FLCAAZSCNC |
| J9312 · Injection, rituximab, 10 mg | 405,213 | $24,453,055 | FLCAAZSCNC |
| 96413 · Administration of chemotherapy into vein, 1 hour or less | 174,866 | $17,514,327 | FLCAAZSCNC |
| J1010 · Injection, methylprednisolone acetate, 1 mg top by services | 1,378,912 | $139,072 | FLCAAZSCNC |
Every code above is searchable free at full depth. Ranking organizations across several codes at once — one combined market view — is part of a Nevvi subscription.
Notify me at launch